Table 4.
Differences in clinical and laboratory variables in patients with liver cirrhosis, including those with hepatocellular carcinoma, and different BCLC scores
| Variable | n | BCLC A | n | BCLC B | n | BCLC C | p |
|---|---|---|---|---|---|---|---|
| BMI (kg/m2), median (Q1-Q3) | 8 | 28.5 (25.2-30.5) | 14 | 29.5 (28.0-31.8) | 14 | 29.0 (28.0-33.8) | 0.609 |
| Age (years), median (Q1-Q3) | 8 | 60.0 (53.0-64.2) | 14 | 65.0 (58.0-70.8) | 14 | 58.5 (52.5-59.8) | 0.134 |
| Sex, n(%) of women | 8 | 3 (37.5) | 14 | 2 (14.3) | 14 | 5 (35.7) | 0.352 |
| Vaspin (ng/ml), median (Q1-Q3) | 8 | 0.5 (0.3-0.6) | 13 | 0.4 (0.2-0.6) | 14 | 0.2 (0.1-0.5) | 0.504 |
| Visfatin, mean ±SD | 8 | 4.8 ±1.9 | 14 | 4.1 ±1.4 | 14 | 4.3 ±2.4 | 0.653 |
| Irisin (μg/ml), median (Q1-Q3) | 8 | 3.4 (1.8-4.4) | 14 | 2.5 (1.8-2.9) | 14 | 2.0 (1.6-2.8) | 0.246 |
| Betatrophin (ng/ml), median (Q1-Q3) | 8 | 39.4 (22.7-47.0) | 13 | 34.3 (25.0-41.7) | 13 | 43.4 (23.8-48.7) | 0.744 |
| Insulin (ng/ml), median (Q1-Q3) | 8 | 1.1 (0.6-1.2) | 14 | 0.8 (0.5-1.2) | 14 | 1.0 (0.5-1.3) | 0.657 |
| Type 2 diabetes, n(%) | 8 | 4 (50.0%) | 14 | 10 (71.4%) | 14 | 10 (71.4%) | 0.526 |
| Hypertension, n(%) | 8 | 2 (25.0%) | 14 | 3 (21.4%) | 14 | 7 (50.0%) | 0.235 |
| Tchol (mg/dl), median (Q1-Q3) | 8 | 153.3 (127.3-161.1) | 14 | 161.9 (137.0-200.9) | 14 | 157.1 (121.5-190.0) | 0.546 |
| TG (mg/dl), median (Q1-Q3) | 8 | 94.4 (67.8-122.3) | 14 | 116.0 (83.2-132.2) | 14 | 120.3 (78.2-134.2) | 0.785 |
| HDL (mg/dl), median (Q1-Q3) | 8 | 40.5 (29.6-45.2) | 14 | 37.0 (32.8-42.2) | 14 | 36.0 (32.7-47.0) | 0.999 |
BCLC – Barcelona Clinic Liver Cancer, BMI – body mass index, TChol – total cholesterol, TG – triglycerides, HDL – high-density lipoprotein